News | February 26, 2013

Sniffing Out the Side Effects of Radiotherapy May Soon Be Possible

February 26, 2013 — Researchers at the University of Warwick and The Royal Marsden NHS Foundation Trust have completed a clinical study that may lead to clinicians being able to more accurately predict which patients will suffer from the side effects of radiotherapy.

Gastrointestinal side effects are commonplace in radiotherapy patients and occasionally severe, yet there is no existing means of predicting which patients will suffer from them. The results of the pilot study, published in the journal Sensors, outline how the use of an electronic nose and a newer technology, FAIMS (field asymmetric ion mobility spectrometry) might help identify those at higher risk.

Warwick Medical School, working in collaboration with the School of Engineering and The Royal Marsden NHS Foundation Trust (led by Dr. J Andreyev), carried out a pilot study to look into the relationship between levels of toxicity in the gut and the likelihood of experiencing side effects.

Dr. Ramesh Arasaradnam, of Warwick Medical School and Gastroenterologist at University Hospitals Coventry and Warwickshire, outlines the results of the study. "In the simplest terms, we believe that patterns in toxicity levels arise from differences in a patient's gut microflora. By using this technology we can analyze stool samples and sniff out the chemicals that are produced by these microflora to better predict the risk of side effects."

The success of the pilot study will lead to a broader investigation into the possible uses of these technologies and could be truly significant in helping clinicians inform patients receiving pelvic radiotherapy, before treatment is started.

Arasaradnam explains what this could mean for radiotherapy patients, "In essence, we will be able to predict those who are likely to develop severe gut related side effects by the pattern of gut fermentation that are altered as a result of radiotherapy. This will enable future directed therapy in these high risk groups."

Dr. James Covington, from the Warwick School of Engineering adds, "This technology offers considerable opportunities for the future. This shows just one application of being able to inform treatment by 'sniffing' patients. We foresee a time when such technology will become as routine a diagnostic test as checking blood pressure is today."

It is further evidence of the ongoing collaboration between Warwick Medical School and School of Engineering. This technology, first developed at Warwick in the early 1990s has been in continuous development ever since, producing some of the most sophisticated chemical sensors and sensor systems available today.

In 2009, the same high tech gas sensor was taken from the automotive world and used to research into quicker diagnosis for some gastrointestinal illnesses and metabolic diseases.

Related Content

Clinical Trial Testing Topical Gel to Reduce Breast Density
News | Breast Density | June 19, 2018
Women with dense breast tissue soon might be adding a new product to their skincare routine to help them fight breast...
New Prostate Cancer Radiotherapy Technique Aims to Preserve Sexual Function
News | Radiation Therapy | June 18, 2018
A multicenter clinical trial being led by UT Southwestern physicians is testing a technique for sparing nerve bundles...
Report Finds Identifying Patients for Lung Cancer Screening Not So Simple
News | Lung Cancer | June 18, 2018
New findings in the current issue of The American Journal of Managed Care suggest that getting the right patients to...
Elekta Unity High-Field MR-Linac Receives CE Mark
News | Image Guided Radiation Therapy (IGRT) | June 18, 2018
Elekta announced that its Elekta Unity magnetic resonance radiation therapy (MR/RT) system has received CE mark,...
Washington University in St. Louis Begins Clinical Treatments With ViewRay MRIdian Linac
News | Image Guided Radiation Therapy (IGRT) | June 14, 2018
June 14, 2018 — The Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine in S
PET/CT Changes Care for 59 Percent of Suspected Recurrent Prostate Cancer Cases
News | Prostate Cancer | June 13, 2018
A recently presented investigational clinical trial evaluated the impact of 18F fluciclovine positron emission...
Accuray TomoTherapy System Beneficial in Two Total Body Irradiation Studies
News | Radiation Therapy | June 13, 2018
Recently published data from two new studies demonstrate the benefits of Accuray’s TomoTherapy System in the delivery...
Women More Likely to Use Other Preventive Health Services Following Mammography
News | Mammography | June 13, 2018
Medicare beneficiaries who undergo breast cancer screening with mammography are more likely than unscreened women to...
Reduced hippocampal volume on MRI

This figure shows reduced hippocampal volume over the course of 6 years as seen on progressive volumetric analysis and also coronal MRI evaluations (arrows).Progressive volume loss in the mesial temporal lobe on MRI is a characteristic imaging feature of AD. This patient was a case of Alzheimer’s Dementia.

 

News | Neuro Imaging | June 12, 2018
According to a UCLA Medical Center study, a new technology shows the potential to help doctors better determine when...
IsoRay Funding Brain Cancer Treatment Research With Ochsner Clinic Foundation
News | Brachytherapy Systems | June 12, 2018
IsoRay Inc. announced the initiation of research funding for brain cancer treatment to Ochsner Clinic Foundation, a not...
Overlay Init